Vol. 3 No. 5 (2023)
Reimbursement Reviews

Amivantamab (Rybrevant)

Published May 10, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses amivantamab (Rybrevant) for injection 50 mg/mL concentrate for solution for IV infusion.
  • Indication: For the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on, or after, platinum-based chemotherapy.